Viva Biotech Holdings (HKG:1873)
1.305
-0.045 (-3.33%)
Oct 22, 2026, 4:08 PM HKT
Viva Biotech Holdings Employees
Viva Biotech Holdings had 2,213 employees as of June 30, 2026. The number of employees increased by 44 or 2.03% since the number was reported on December 31, 2025. That makes Viva Biotech Holdings the 9,653rd largest employer in the world and 716th in Hong Kong.
Employees
2,213
Change
44
Growth
2.03%
Revenue / Employee
993.32K HKD
Profits / Employee
92.88K HKD
Market Cap
2.71B
Employees Chart
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 2,213 | 44 | 2.03% |
| Dec 31, 2025 | 2,169 | 106 | 5.14% |
| Dec 31, 2024 | 2,063 | -14 | -0.67% |
| Dec 31, 2023 | 2,077 | -524 | -20.15% |
| Dec 31, 2022 | 2,601 | 474 | 22.28% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Frontage Holdings | 1,800 |
| Medtide | 596 |
| BioDlink International Company | 594 |
| Jiangsu Recbio Technology | 466 |
| Shanghai Bao Pharmaceuticals | 364 |
| Qyuns Therapeutics | 353 |
| Mirxes Holding Company | 347 |
| Beijing Luzhu Biotechnology | 213 |
Viva Biotech Holdings News
- 1 month ago - Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth - PRNewsWire
- 6 months ago - Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up - PRNewsWire
- 7 months ago - Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA - PRNewsWire
- 9 months ago - Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities - PRNewsWire
- 10 months ago - Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. - PRNewsWire
- 1 year ago - Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry - PRNewsWire
- 1 year ago - Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights - PRNewsWire
- 1 year ago - Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth - PRNewsWire